主页 > 医学讨论 >
【技术产业】Viamet 药业获得400万美元首轮风险基
Intersouth Partners, which was the founding investor in the firm with angel funding, co-led the Series A round along with Hatteras Venture Partners. The investment is the first for Hatteras out of a new fund it has closed. Hatteras, which is based in RTP, has $100 million under management.
Garheng Kong of Intersouth, who had already been a member of Viamet’s board, likes what he sees in the company’s future.
Intersouth, which is based in Durham, “seeded” Viamet in 2006, but the investment was not disclosed, according to Suzanne Cantando of Intersouth. Kong has worked closely with Viamet’s management over the past six months in helping the company close on the new funding as well as advancing its overall development.
“The technology is promising and there are significant market opportunities being pursued,” said Kong, who earned a medical degree had Duke University. According to the National Institutes of Health, metalloenzymes are a “diverse class of enzymes that require a catalytic metal ion for activity.”
Viamet is exploring the use of inhibitors based on metalloenzymes to fight infectious diseases, inflammation and oncology. The company is developing what it calls “novel therapeutic agents” that will target metalloenzymes or disrupt a cell’s ability to utilize metal ions such as zinc and iron.
Douglas Reed of Hatteras Ventures will also join the Viamet board.
“This Series A financing will support the rapid development of our metalloenzyme inhibitor programs,” said Robert Schotzinger, the chief executive officer of Viamet. Viamet was launched in 2005.
Douglas Reed of Hatteras Ventures will oin the Viamet board as part of the deal. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-31 17:11
医学,生命科学网